San Francisco / Consultant Medical Oncologist / Tokyo / London / /
Company
The Royal Marsden NHS Foundation Trust / Astellas Pharma Europe Ltd. / Astellas Pharma Inc. / Medivation Inc. / Tokyobased Astellas Pharma Inc. / Macmillan / European Cancer Patient Coalition / /
Continent
Africa / Europe / South America / /
Country
Switzerland / South Africa / Norway / Japan / United States / Brazil / Canada / Australia / Liechtenstein / United Kingdom / /
Currency
USD / / /
Event
FDA Phase / Business Partnership / /
Facility
European Headquarters of Tokyobased Astellas Pharma Inc / European Headquarters of Tokyo-based Astellas Pharma Inc. / The Institute of Cancer Research / /
IndustryTerm
treatment of these diseases / pharmaceutical / therapy for advanced prostate cancer / Therapies for Castration-Resistant Prostate Cancer / biopharmaceutical / pharmaceuticals / prostate cancer therapeutics / /
MedicalCondition
common disease / headache / metastatic castration-resistant prostate cancer / prostate cancer / advanced prostate cancer / cancer / disease / Seizure / diseases / /
MedicalTreatment
chemotherapy / Hormonal therapy / cancer therapeutics / /
Organization
World Health Organization / Committee for Medicinal Products for Human Use / European Parliament / Drug Development Unit / European Medicines Agency / Institute of Cancer Research / London / and Consultant Medical Oncologist / U.S. Food and Drug Administration / European Commission / European Union / NHS / Institute of Cancer Research / /
Person
Erik Briers / Nat / de Bono / Claire Nicholson Mindy / Mindy Dooa Red / / /
Position
Executive Director / Head / Professor of Experimental Cancer Medicine / Professor / Director / /
Product
testosterone / enzalutamide / MDV3100 / /
ProvinceOrState
California / /
PublishedMedium
Cancer Research / /
Region
Middle East / /
Technology
DNA binding / apoptosis / chemotherapy / Drug Development / /
XTANDI™▼ (ENZALUTAMIDE) AUTHORISED IN THE EUROPEAN UNION (EU) FOR ADVANCED PROSTATE CANCER Enzalutamide authorised in European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate c